Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy

This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy

• Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day)
• Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo

Inclusion Criteria:

• Type 2 Diabetes nephropathy
• Urinary albumin excretion 1-3g/24hours
• Serum creatinine < 3mg/dl

Exclusion Criteria:

• Type 1 diabetes mellitus
• Renal diseases other than type 2 Diabetes nephropathy
• Renal artery stenosis
• Severe heart diseases
• Tuberculosis